These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 4200340)

  • 41. [Hyperlipoproteinemia type 3. Report on 5 cases].
    Weber K; Braun-Falco O; Wolfram G
    Hautarzt; 1973 May; 24(5):179-85. PubMed ID: 4753368
    [No Abstract]   [Full Text] [Related]  

  • 42. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diet, lipids, lipoproteins and glucose tolerance in patients with peripheral obliterating arteriopathy].
    Mantero O; Conti F; Biasi G; Sirtori R
    Boll Soc Ital Cardiol; 1975; 20(10):1141-4. PubMed ID: 1241952
    [No Abstract]   [Full Text] [Related]  

  • 44. [The prevalence of lipid metabolism disorders in rheumatological diseases].
    Frank O; Tidl G
    Wien Med Wochenschr; 1974 Sep; 124(37):527-30. PubMed ID: 4547104
    [No Abstract]   [Full Text] [Related]  

  • 45. [Significance of hyperlipoproteinemia in diabetes mellitus].
    Gligore V; Hincu N; Tecuceanu R; Sopon E; Hoinărescu E; Cristea A
    Med Interna (Bucur); 1973 Oct; 25(10):1259-72. PubMed ID: 4792521
    [No Abstract]   [Full Text] [Related]  

  • 46. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM; Levy RI
    Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical trial of methyl clofenapate (a derivative of clofibrate) in patients with essential hyperlipidaemias--with special reference to type II (primary) hyperlipidaemia.
    Craig GM; Walton KW
    Atherosclerosis; 1972; 15(2):189-98. PubMed ID: 4579956
    [No Abstract]   [Full Text] [Related]  

  • 48. [Hypolipemic property and myotoxic action of clofibrate in a case of nephrotic syndrome].
    Fabre J; Denizot M; Wildi E; Micheli H; Berthoud S
    Schweiz Rundsch Med Prax; 1973 Jun; 62(23):732-7. PubMed ID: 4705828
    [No Abstract]   [Full Text] [Related]  

  • 49. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bilateral parotid gland enlargement and hyperlipoproteinemia.
    Kaltreider HB; Talal N
    JAMA; 1969 Dec; 210(11):2067-70. PubMed ID: 5395209
    [No Abstract]   [Full Text] [Related]  

  • 52. [Effect of chlorfibrinic acid on the triglyceride and glycogen contents of human liver as well as on blood-level forming metabolites].
    Hanefeld M; Jaross W; Trübsbach A; Leonhardt W
    Z Gesamte Inn Med; 1972 Aug; 27(15):655-8. PubMed ID: 4629764
    [No Abstract]   [Full Text] [Related]  

  • 53. [Lipoproteins and hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Fortschr Med; 1978 Sep; 96(35):1746-8. PubMed ID: 738685
    [No Abstract]   [Full Text] [Related]  

  • 54. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clofibrate treatment of hyperlipidemia in long-term dialysis patients].
    Wessels G; Müller H; Busch G; Loew H
    Med Welt; 1976 Nov; 27(47):2278-9. PubMed ID: 826753
    [No Abstract]   [Full Text] [Related]  

  • 56. [Primary hyperlipoproteinemia of type V].
    Kucerová L; Voslárová Z; Papezová R
    Vnitr Lek; 1974 Sep; 20(9):869-76. PubMed ID: 4410504
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical evaluation of the therapeutic activity of the -pyridyl-carbinol ester of clofibric acid].
    Silingardi V; Renzi R; Mora A; Di Prisco AU
    Minerva Med; 1973 Mar; 64(16):751-69. PubMed ID: 4704721
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparative study of triglyceridemia, lipemia, glycemia and weight index in patients with high and normal serum uric acid].
    Kuntz D; Rouques C; Paolaggi F; Ryckewaert A
    Pathol Biol (Paris); 1969 Apr; 17(7):399-403. PubMed ID: 4893908
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.